Several multi-targeting agonists at GIPR, GLP-1R or GCGR, developed to maximize metabolic benefits with reduced side-effects, are in clinical trials to treat type 2 diabetes and obesity
Instead of judging progress by the scale alone, clinicians may also track waist measurements, blood pressure, glucose markers, energy level, strength, and how clothing fits
In parallel, Eli Lillys Foundayo (orflorglipron), a small molecule oral GLP-1, reached the US market in April 2026, opening a new competitive front against Novo Nordisks oral Wegovy
In the context of ER stress, the RIDD pathway plays a cytoprotective role, while IRE1 promotes the production of XBP1s, which in turn promotes the expression of genes beneficial to ER stress recovery (Shishova et al., 2022)
10.3390/ijms22168792 24 RubioF
R.GrnerR.NoeskeR.ErslandL